SRI Bioscience Awarded $14.7 Million Contract to Continue Development of High-Concentration Naloxone Formulation

MENLO PARK, Calif.: MENLO PARK, Calif., Dec. 8, 2021 /PRNewswire/ -- SRI Biosciences has been awarded a $14.7 million contract sponsored by the Defense Threat Reduction Agency (DTRA) through the Medical, Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC) to continue development of a high-concentration naloxone product for intravenous, intramuscular...

Click to view original post